PTK2 and glioblastoma: FAK and BAX were identified as potential targets for GBM treatment, while samples in cluster 1 with higher BCLXL levels could be treated with BH3 mimetics, and those with elevated SMAC/DIABLO levels could benefit from Smac inhibitor therapy [23–25].